Genomic DNA from 32 unrelated families with male-limited precocious puberty was examined for the previously described Asp-578 --Gly, 
among the remaining four families with the inherited form and in four sporadic cases of the disorder. an A -> C transversion resulting in substitution of leucine for Ile-542 in the fifth transmembrane helix, an A -> G transition resulting in substitution of glycine for Asp-564 in the third cytoplasmic loop, a G T transversion resulting in substitution of tyrosine for Asp-578 in the sixth transmembrane helix, and a T -* C transition resulting in substitution of arginine for Cys-581 in the sixth transmembrane helix. Human embryonic kidney cells transfected with cDNAs for each of the mutant hLHRs, created by PCR-based mutagenesis of the wild-type hLHR cDNA, exhibited increased levels of basal cAMP production in the absence of agonist, indicating constitutive activation of the mutant hLHRs. Three of the additional mutations had specific features: Leu and Cys-581 --Arg appeared ligand-unresponsive, whereas Asp-578 -* Tyr appeared to correlate genotype with phenotype. We conclude that the region spanning nt 1624-1741 of exon 11 is a hotspot for heterogeneous point mutations that constitutively activate the hLHR and cause male-limited precocious puberty.
Familial male-limited precocious puberty (FMPP) is a form of isosexual precocious puberty in boys in which testosterone levels are elevated independent of changes in luteinizing hormone-releasing hormone and serum luteinizing hormone levels (1) (2) (3) . Signs of puberty usually appear by 3-4 yr of age, and testicular biopsy specimens show Leydig cell hyperplasia (1, 2) . The pattern of inheritance is autosomal dominant, although sporadic cases occur.
Three mutations spanning amino. acid residues 571-578 of the human luteinizing hormone receptor (hLHR) have been described among 17 families with FMPP (4) (5) (6) (7) (8) . Substitution of glycine for Asp-578 in the sixth transmembrane helix of the hLHR was found in nine different families with the dominantly inherited form (4, 5) and in five sporadic cases of FMPP (7, 8) . This mutant receptor produced increased levels of basal cAMP, consistent with constitutive activation of the hLHR (4). Substitution of isoleucine for Met-571 and isoleucine for Thr-577 in the sixth transmembrane helix was found in three additional FMPP kindreds; however, expression studies to confirm constitutive activation of these mutant hLHRs have not been reported (5, 6 To address these further questions, genomic DNA from 32 unrelated families affected with FMPP was examined for mutations of the hLHR gene. In addition to the Asp-578 -> Gly mutation, four additional point mutations were identified in eight families (four inherited and four sporadic cases) within transmembrane helices 5 and 6, and the intervening third cytoplasmic loop of the hLHR, spanning residues 542-581. Each of these hLHR mutants produced elevated levels of cAMP when expressed in 293 cells. These four additional activating mutations included two with distinctive patterns of receptor activation that yield insights into mechanisms of receptor signal transduction. (13) . The composition of the PCR buffer and conditions were as described (14) . After the reaction, excess primers and salts were removed, and the amplified product was concentrated by using a Centricon-100 microcentrator (Amicon). The nucleotide sequence of the amplified DNA was determined by a modified dideoxynucleotide chaintermination method using Sequenase (United States Biochemical), as described (15) . All mutations were determined by sequencing both strands generated by asymmetric PCR. Templates for asymmetric PCR were derived from two or more independent PCR products.
MATERIALS AND METHODS
Construction of cDNA Clones for Expression Studies of Mutant Receptors. All four receptor mutations were located between a unique Xba I site (nt 1383-1388) in the hLHR gene (16) and a BamHI site in the cloning vector (pCMX). Thus, two oligonucleotide primers flanking these sites (primer A, corresponding to nt 1375-1393, 5'-GTCATCACTCTAGA-AAGAT; primer B, corresponding to nt 2097-2080 plus a 9-nt 5' extension carrying a BamHI restriction site, 5'-CGGGATC-CTTTAACACTCTGTGTAGCG) were used with primers incorporating specific mutations for PCR amplification to obtain the mutant cDNA fragments. For all mutations, primers containing the mutated nucleotide were flanked on the 5' end by specific restriction enzyme sites. For mutation 542, primers A and 542W [wild type (WT), nt 1619-1598, 5'-AAGAAG-GCCACCACATTGAGAA], and primers 542M (mutant, nt 1606-1632; A1624C, 5'-GTGGTGGCCTTCTTCATACTT-TGTGCT) and B, respectively, were used to generate two cDNA fragments. After restriction enzyme digestion the two cDNA fragments were joined at the Hae III restriction site, together with the flanking sequences of the WT hLHR cDNA, to replace the Xba I-BamHI fragment of the WT hLHR cDNA in the cloning vector. With the same method, the other three mutations were introduced by using primers 564M (nt 1667-1694; A1691G, 5'-CAGAATTAATGGCTACCAA-TAAAGGTAC), 578M (nt 1755-1727; G1732T, 5'-GATAG-GTGCCATGCAGGTGAAATAGGTGA) and 581M (nt 1760-1733; T1741C, 5'-AAAGAGATAGGTGCCATGCGG-GTGAAAT). A Ban I restriction site is present in primers 578M and 581M, whereas anAsn I site is present in the 564M primer.
Individual cDNA fragments were amplified in a 50-,lI reaction mixture containing 20 mM Tris (pH 8.8), 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.1% Triton X-100, 200,M of each dNTP, 1 ,tM of each primer, and 2.0 units of Vent DNA polymerase (New England Biolabs). Using the WT hLHR cDNA cloned into the pCMX vector (pCMXhLHR) as template, samples were subjected to 10 cycles of amplification, followed by incubation for 10 min at 72°C. Each pair of the cDNA fragments for a specific mutation was digested withXba I, BamHI, and the indicated restriction enzymes, before ligation into a truncated pCMXhLHR vector which had the corresponding Xba I-BamHI fragment removed. The ligation mixtures were used to transform Escherichia coli strain JM109.
Ligated clones for mutations Asp-564 --Gly and Cys-581 --Arg were screened by enzyme digestion with Rsa I and Aci I, respectively. All mutants were sequenced (Sequenase, United States Biochemical) to confirm the presence of the intended mutation and the absence of unintended PCR-generated mutations.
Exponentially growing human embryonic kidney (293) cells in Dulbecco's modified Eagle's medium/5% calf serum/ penicillin at 100 ,ug/ml/streptomycin at 100 ,ug/ml gentamycin at 100 ,ug/ml were plated (2 x 106 cells) in 100-mm dishes. Cells were transfected by the calcium phosphate precipitation method with 15 jig of DNA per dish (17) . Equivalent transfection efficiency was confirmed by cotransfecting pRSV-3-gal and measuring ,3-galactosidase activity in the cells.
The signal transduction activity of expressed receptors was estimated by determining cAMP production with and without exposure to human chorionic gonadotropin (hCG). Fortyeight hours after transfection, 293 cells were washed, transferred to 24-well tissue culture plates (2 x 106 cells per well), and treated with 0.1-1000 ng of hCG per ml (CR-127; 14,900 international units/mg) in the presence of 0.25 mM methyl isobutylxanthine and 5% calf serum for 16 hr at 370C. Cyclic AMP accumulation was measured by RIA (18) .
RESULTS
Msp I restriction digests of PCR product encoding residues 441-594 indicated the previously described Asp-578 --Gly mutation in 24 of the 32 families. These 24 families had a family history of FMPP. PCR product from the eight families that did not cut with Msp I revealed four unreported mutations. (i) An A -> C transversion at nt 1624 in codon 542 was found in four unrelated families (Fig. lA) . This mutation causes substitution of leucine for isoleucine in the fifth transmembrane helix (Fig.  2) and creates a recognition site for the enzyme TspS091.
Three of these families had a history of FMPP extending over multiple generations. The fourth boy was a sporadic case whose mother and father had only the WT sequence.
(ii) A second mutation, an A -> G transition at nt 1691 in codon 564, was found in one affected boy (Fig. 1B) . This mutation causes substitution of glycine for aspartate in the third cytoplasmic loop (Fig. 2) and creates a recognition site for Rsa I (19) . Maternal PCR product did not cut with Rsa I. Paternal DNA could not be obtained; however, the father's height was 188 cm, and the onset of puberty was said to be normal. No other male family members had a known history of precocious puberty or short stature.
(iii) The third mutation, a G -* T transversion at nt 1732 in codon 578, was found in two affected boys (Fig. 1 C) . This mutation causes substitution of tyrosine for aspartate in the sixth transmembrane helix (Fig. 2) . There was no family history of precocious puberty, and direct sequencing of PCR product from the mother and father of both boys did not reveal the mutation.
(iv) The fourth mutation, a T -> C transition at nt 1741 in codon 581, was found in one family in which FMPP extended over two generations (11) (Fig. 1D) . This mutation causes substitution of arginine for cysteine in the sixth transmembrane helix (Fig. 2) basal cAMP production as cells transfected with vector DNA. hCG (0.1-1000 ng/ml) produced a concentration-dependent increase in cAMP production in cells expressing the WT hLHR with an EC50 of 25 ng/ml and mean stimulation of 25-fold (range 19-to 33-fold, n = 5) (Fig. 3) . In contrast, the Asp-564 mutant hLHR had elevated basal cAMP production that was further stimulated by hCG in a dose-dependent A manner (EC50 of 6.6 ± 1.8 ng/ml, n = 4). Maximum cAMP production of this mutant was lower than that of the WT hLHR. We further tested cAMP production by all mutants. Compared with the WT hLHR, all the mutant hLHRs produced higher basal levels of cAMP in 293 cells, consistent with constitutive activation (Fig. 4) . The highest basal cAMP production of two of the four mutations (Asp-564 -* Gly and Asp-578 -+Tyr) could be further increased by hCG stimulation (Fig. 4) . However, maximal hCG-stimulated (1000 ng/ml) cAMP levels in the Ile-542 --Leu and Cys-581 --Arg mutant hLHR-transfected cells did not significantly exceed the basal cAMP levels in the absence of hormone (Fig. 4) . tions that constitutively activate the hLHR and cause FMPP have been described. These four mutations represent 57% of the seven known mutations and, therefore, extend the concept of genetic heterogeneity of activating hLHR mutations in this disorder.
(ii) In contrast to previous reports in which 100% of sporadic cases of FMPP were due to Asp-578 -* Gly (7, 8) , none of our sporadic cases had this mutation; all had other mutations. Therefore, among the four mutations now associated with all the known sporadic cases, the relative frequency of the Asp-578 -> Gly mutation is only 56%. Consequently, sporadic cases of FMPP should be viewed as having a high likelihood of being associated with other mutations. Pedigree analysis of our 24
families with the Asp-578 --Gly mutation did not reveal any discernible relationships among the families. Because these 24 families, when added to the 14 previously reported cases with
Asp-578 -* Gly (4-8), comprise 38 kindreds from widely disparate geographic regions, it is unlikely that they all share a common ancestral origin.
(iii) The comprehensive nature of our study now permits the relative frequency of the seven different constitutively activating mutations of the hLHR to be calculated. The Asp-578 -* Gly mutation is by far the most common; however, its overall incidence in FMPP is 78%, rather than 100% as found initially (4) . The next most common mutation is Ile-542 -* Leu with an overall incidence of 8%. Of the four families with this mutation, three had the inherited form of FMPP, whereas one case was sporadic. Thus, for the inherited form of FMPP, Asp-578 found in four families collectively account for the remaining 10% of inherited cases of FMPP.
(iv) Differences in phenotypic expression of FMPP may be explained by differences in basal hLHR activity. A previously reported case from Scotland presented at 1 yr of age with signs of pubertal development (12 elevated levels of basal cAMP, they did not further increase cAMP production in response to hCG. These are then two constitutively activating mutations of the hLHR that appear ligand-unresponsive. Although reproductive potential is not impaired by these mutations, the clinical significance of this finding will require additional study. We speculate that alterations of Ile-542 and Cys-581 may disrupt the proposed low-affinity ligand-binding domain within the membrane and thereby impede ligand-binding and/or signal transduction.
(v) The region in which activating hLHR mutations have been found is no longer constrained between residues 571 and 578 in the sixth transmembrane helix. We have described four additional activating mutations that encompass the fifth transmembrane helix, the intervening third cytoplasmic loop, and further down the sixth transmembrane helix. The region containing the known activating mutations now includes residues 542-581. Thus, there is a much wider region containing at least 120 bp within exon 11 that contain hotspots for receptor activation.
(vi) All seven known constitutively activating mutations of the hLHR gene in patients with FMPP resulted from a single-base-pair substitution in exon 11. Neither insertions, microdeletions, chain terminations, nor translocations have been found in exon 11, nor have mutations in other regions of the hLHR been identified as causes of FMPP.
Of the seven mutations observed in FMPP, three substitute a neutral or nonpolar residue for the acidic residue aspartate, two substitute the nonpolar residues isoleucine and methionine with another nonpolar residue (leucine or isoleucine) of similar size, one substitutes a nonpolar residue (isoleucine) for a polar residue (threonine), and one substitutes the basic residue arginine for cysteine. Five mutations (Ile-542 -> Leu, Asp-564 --Gly, Thr-577 --Ile, Asp-578 -> Gly, Cys-581 -> Arg) either create or delete recognition sites for restriction endonucleases, which facilitates rapid screening for these defects. The residues Ile-542, Asp-564, Asp-578, and Cys-581 are conserved in the glycoprotein hormone receptors. Ile-542 and Cys-581 are also found in the family of human opsins and rhodopsin, whereas Cys-581 is found in the human thromboxane A2 receptor, a-and ,B-adrenergic, dopamine, and serotonin receptors (20) , suggesting that this is a highly conserved residue with an important role in receptor function.
Implicit in the activation of G protein-coupled receptors is a release of conformational constraints following ligand binding (21, 22) . Five human diseases are known to be caused by constitutive activation of G protein-coupled receptors: retinitis pigmentosa due to mutant rhodopsin (23), hyperfunctioning thyroid adenomas and autosomal dominant toxic thyroid Proc. NatL Acad Sci. USA 92 (1995) hyperplasia due to mutations in the thyroid-stimulating hormone receptor gene (24, 25) , autosomal dominant hypocalcemia due to a mutation in the calcium-sensing receptor gene (26) , and FMPP due to mutations in the hLHR gene (4) (5) (6) (7) (8) . Rhodopsin is maintained in an inactive state by a salt bridge between Glu-113 and Lys-296 in the third and sixth transmembrane helices, respectively (27, 28) . Mutations in either residue abolish this salt bridge and cause constitutive activation of rhodopsin. The Asp-578 -k Tyr and Asp-564 -* Gly mutations of the hLHR, like the Asp-578 --Gly mutation, substitute a neutral for an acidic residue and thus might disrupt either electrostatic or hydrogen bond interactions with residues in adjacent helices, analogous to the activating mutations in rhodopsin. The Ile-542 -* Leu, Thr-577 --Ile, and Met-571 -.
Ile mutations are conservative, substituting one nonpolar residue with another. However, because of change in size or bulkiness of side chains, these substitutions may also modify the relative positions of helices 5 and 6 and the position or accessibility of the third cytoplasmic loop, allowing the hLHR to assume a partially active conformation. Substitution of Cys-581 by arginine introduces a positively charged residue into helix 6, which is likely to disrupt electrostatic or hydrogen bond interactions with adjacent helices.
In summary (see Table 1 ), we have identified four additional point mutations within transmembrane helices 5 and 6 and the intervening third cytoplasmic loop of the hLHR that are responsible for constitutive activation of testis Leydig cells, leading to FMPP. The mutations Asp-578 -> Gly and Ile-542 --Leu account for 90% of the inherited forms of FMPP. Three of our additional mutations were found in sporadic cases of FMPP; therefore, Asp-578 --Gly can no longer be presumed to account for all sporadic cases. Two other patterns of activating hLHR mutations have been identified: one where a genotype leading to higher basal cAMP formation appears to correlate with the phenotype of earlier clinical expression and one where the constitutively activated mutant receptors are ligand-unresponsive. Knowledge of these additional mutations will facilitate genetic counseling and diagnosis, as well as provide the basis to study the three-dimensional conformation of the receptor domains involved in ligand-binding and G protein activation.
